Check patentability & draft patents in minutes with Patsnap Eureka AI!

Application of Capilliposide A and homologues thereof in preparation of medicine for treating rheumatoid arthritis

A homologue and rheumatoid technology, applied in the field of biomedicine, can solve the problems of no relevant research on the therapeutic effect, and achieve the effects of reducing inflammatory cell infiltration, improving synovial lesions, and improving activity status

Pending Publication Date: 2022-08-05
中国科学院基础医学与肿瘤研究所(筹)
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] LC-A and its homologues are oleanane triterpene saponins with 13,28-epoxy structure, which are a class of compounds with anti-tumor effects in the natural plant Herb Herb. There is no relevant research on the therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Capilliposide A and homologues thereof in preparation of medicine for treating rheumatoid arthritis
  • Application of Capilliposide A and homologues thereof in preparation of medicine for treating rheumatoid arthritis
  • Application of Capilliposide A and homologues thereof in preparation of medicine for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Seed macrophages RAW264.7 in 96-well plates at a density of 1 × 10 per well 4 cell. After the cells adhered to the wall, dosing treatment was carried out, and the dosing amount was not higher than 40uM. The cells were divided into control group, model group, LC-A low-dose group, LC-A high-dose group, the control group was treated with solvent DMEM medium, the model group was treated with medium containing 5 μg / ml LPS, and the low-dose group was treated with medium containing 5 μg / ml LPS. The medium containing 5 μg / ml LPS and 20 μM LC-A was treated, and the high-dose group was treated with the medium containing 5 μg / ml LPS and 30 μM LC-A. The concentrations mentioned above are the final concentrations. After 24 hours of treatment, the supernatant of the medium was taken, the content of nitric oxide was detected by Griess reagent, and the concentration of inflammatory factors TNF-α and IL-6 was detected by enzyme-linked immunosorbent assay kit. The result is as figure ...

Embodiment 2

[0029] Seed macrophages RAW264.7 in 6-well plates at a density of 1 × 10 6 Cell / well, shake gently to make the cells evenly distributed, put it into a cell culture incubator for 24 hours, make the cells adhere to the wall, and then add medicines, and the dosage is not higher than 40uM. The control group was treated with solvent DMEM medium, the model group was treated with medium containing 1 μg / ml LPS, the low-dose group was co-treated with medium containing 1 μg / ml LPS and 10 μM LC-A, and the high-dose group was treated with a medium containing 1 μg / ml LPS LPS and 20 μM LC-A medium were co-treated, and the concentrations indicated above were final concentrations. After 24 h of treatment, cells were lysed with RIPA lysis buffer (containing protease inhibitor PMSF), and the cell protein lysis buffer was quantified as a protein sample containing loading buffer with a protein concentration of 1 μg / μl using BCA kit. Western blotting was used to determine the phosphorylation leve...

Embodiment 3

[0031] Six-week-old rats were selected and divided into control group, model group, LC-A low-dose group, LC-A medium-dose group, and LC-A high-dose group. After adaptive feeding, the control group was subcutaneously injected with 0.2 ml of normal saline at the root of the tail, and the model group and the administration group were subcutaneously injected with 0.2 ml of bovine type II collagen emulsified with incomplete Freund's adjuvant 1:1 at the root of the tail, recorded as Day0 . Booster immunization was performed on Day 7. The control group was injected subcutaneously with 0.2 ml of normal saline at 1.5 cm at the base of the tail, and the model group and the administration group were injected with 0.2 ml of bovine type II collagen emulsified with complete Freund's adjuvant 1:1. Starting from Day 8, the rats were given daily intragastric administration with a volume of 1ml / 100g body weight for 14 consecutive days. LC-A was prepared with a physiological saline solution with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Capilliposide A and a homologue thereof in preparation of a medicine for treating rheumatoid arthritis. The Capilliposide A and the homologues thereof can relieve red and swollen symptoms of rheumatoid arthritis, reduce inflammatory cell infiltration of joint tissues, improve articular cartilage and synovial membrane lesions and improve the activity state of joints, are good in safety and have a relatively good development prospect.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of Capilliposide A (hereinafter referred to as LC-A) and its homologues in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid Arthritis (RA) is a chronic autoimmune disease and the most common clinical manifestation of inflammatory arthritis. As one of the main causes of disability and disability, RA is a long-term threat to the health of people around the world. According to statistics, 0.5-1% of the world's population suffers from RA. In my country, the incidence of RA is about 0.34%, and there are 5 million newly diagnosed cases of RA every year. The pathogenesis of RA is complex and unclear, in part due to its heterogeneity, in which different physiopathological factors ultimately activate common inflammatory pathways, resulting in patients with similar clinical manifestations of arthritis. Rheumato...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P19/02A61P37/02A61P19/08A61P19/04
CPCA61K31/704A61K9/0053A61K9/0014A61P19/02A61P37/02A61P19/08A61P19/04
Inventor 韩昊特沈宇航田景奎李守信王露萍韩卓朱玮
Owner 中国科学院基础医学与肿瘤研究所(筹)
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com